1. Scrip
  2. >>Business
  3. >>Strategy

Vir Scores In Oncology Pivot With Strong Early T-Cell Engager Results

 
• By Alaric DeArment

Five months after taking over the dual-masked T-cell engagers from Sanofi amid a restructuring, the company posted promising initial Phase I data from its PSMA- and HER2-targeting IO candidates.

• Source: Shutterstock

Vir Biotechnology’s move from focusing solely on antiviral drugs to incorporating oncology into its pipeline has shown early signs of potentially paying off as the company announced safety and efficacy data for two T-cell engager (TCE) antibodies, VIR-5818 and VIR-5500, which it licensed from Sanofi in August.

The San Francisco-based biotech announced 8 January what it called encouraging safety and efficacy data from dose-escalation trials of VIR-5818,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

More from Therapy Areas

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.